目的:分析奥氮平治疗大鼠中缝背核差异表达蛋白,探讨奥氮平治疗早期代谢紊乱的可能机制。
方法:20只雄性和20只雌性SD大鼠随机均分为奥氮平组和对照组,每日给予奥氮平及生理盐水治疗4周,分别。最后一次治疗后一小时,采用iTRAQ结合液相色谱-串联质谱(LC-MS/MS)对大鼠的中缝背核进行蛋白质组学分析.GO,KEGG通路,COG,进行了差异表达蛋白的途径和蛋白相互作用网络分析.从蛋白质组列表中选择了几个靶基因,以及使用实时实时定量PCR和Western印迹进行相同分组和治疗的另外24只小鼠的背中缝核中的表达水平。
结果:在奥氮平治疗的小鼠的背中缝核中总共鉴定出214种差异表达蛋白,包括72个未调节和142个下调的蛋白质。GO分析表明,差异表达的蛋白质在细胞过程中富集,生物调节,代谢过程,对刺激的反应,多细胞组织过程,绑定,催化活性,分子功能调节因子和转录调节因子活性。KEGG分析表明,这些蛋白质在流体剪切应力和动脉粥样硬化中富集,血清素能突触,丁酸代谢,甲状腺激素合成与IL-17信号通路.差异表达蛋白Cav1,Hsp90b1,Canx,Gnai1,MAPK9和LOC685513位于蛋白质-蛋白质相互作用网络的节点,与代谢紊乱密切相关。在奥氮平治疗的小鼠中,细胞凋亡负调节因子Hmgcs2的表达,中缝背核显著下调,其中Pla2g4e的表达式,参与5-羟色胺能突触的Slc6a4和Gnai1显着上调。
结论:在治疗的早期阶段,奥氮平可能通过调节Cav1、Hsp90b1、Canx、中缝背核中的Gnai1、MAPK9、LOC685513(Gng14)和5-HTR2突触相关蛋白。
OBJECTIVE: To analyze the differentially expressed proteins in the dorsal raphe nucleus of rats treated with olanzapine and explore the possible mechanism of metabolic disorders in the early stage of olanzapine treatment.
METHODS: Twenty male and 20 female SD rats were both randomized equally into olanzapine group and control group for daily treatment with olanzapine and saline for 4 weeks, respectively. One hour after the last treatment, the dorsal raphe nucleus of the rats was dissected for proteomic analysis using iTRAQ combined with liquid chromatography-tandem mass spectrometry (LC-MS/MS). GO, KEGG pathway, COG, pathways and protein interaction network analyses of the differentially expressed proteins were performed. Several target genes were selected from the proteomic list, and their expression levels in the dorsal raphe nucleus of another 24 mice with identical grouping and treatment using real time real-time quantitative PCR and Western blotting.
RESULTS: A total of 214 differentially expressed proteins were identified in the dorsal raphe nucleus of olanzapine-treated mice, including 72 unregulated and 142 downregulated proteins. GO analyses showed that the differentially expressed proteins were enriched in cellular process, biological regulation, metabolic process, response to stimulus, multicellular organismal process, bindings, catalytic activity, molecular function regulator and transcription regulator activity. KEGG analysis suggested that these proteins were enriched in fluid shear stress and atherosclerosis, serotonergic synapse, butanoate metabolism, thyroid hormone synthesis and IL-17 signaling pathway. The differentially expressed proteins Cav1, Hsp90b1, Canx, Gnai1, MAPK9, and LOC685513 were located at the nodes of the protein-protein interaction network in close relation with metabolic disorders. In olanzapine-treated mice, the expression of Hmgcs2, a negative regulator of apoptosis, was significantly down-regulated in the dorsal raphe nucleus, where the expressions of Pla2g4e, Slc6a4 and Gnai1 involved in serotonergic synapse were significantly upregulated.
CONCLUSIONS: In the early stage of treatment, olanzapine may contribute to the occurrence of metabolic disorders in rats by regulating the expressions of Cav1, Hsp90b1, Canx, Gnai1, MAPK9, LOC685513 (Gng14) and 5-HTR2 synapse-related proteins in the dorsal raphe nucleus.